Edition:
United Kingdom

Selecta Biosciences Inc (SELB.OQ)

SELB.OQ on NASDAQ Stock Exchange Global Market

12.21USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$12.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
74,897
52-wk High
$24.00
52-wk Low
$8.00

Select another date:

Wed, May 9 2018

BRIEF-Selecta Biosciences Announces Q1 Loss Per Share $0.71

* SELECTA BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Selecta Biosciences Qtrly Loss Per Share $0.88

* SELECTA BIOSCIENCES ANNOUNCES FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Selecta Appoints ‍Gabriel Pirona As New Chief Financial Officer

* ‍HUGUES ROUGIER WILL RESIGN FROM HIS ROLE AS CHIEF FINANCIAL OFFICER

BRIEF-Selecta Biosciences Says Expects To Report Initial Results For Phase 2 Clinical Trial Of SEL-212 In Chronic Severe Gout In April 2018

* SELECTA BIOSCIENCES SAYS EXPECTS TO REPORT INITIAL RESULTS FOR PHASE 2 CLINICAL TRIAL OF SEL-212 IN CHRONIC SEVERE GOUT IN APRIL 2018 - SEC FILING

BRIEF-Selecta Biosciences Says CEO Werner Cautreels Plans Retirement at 2018 End

* SELECTA BIOSCIENCES ANNOUNCES CEO’S INTENT TO RETIRE AND TRANSITION PLAN

BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy

* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY

Select another date: